What are CXCR4 antagonist drugs?

CXCR4 antagonist drugs are pharmacologic agents that share a common mechanism (typically targeting CXCR4). 1 are currently marketed, with 2 more in clinical development.

What are the marketed CXCR4 antagonist drugs?

Marketed CXCR4 antagonist drugs include Fixed Dose Plerixafor.

CXCR4 antagonist

1 marketed 2 in Phase 3

This page covers all CXCR4 antagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CXCR4.

Targets

CXCR4

Marketed (1)

Fixed Dose Plerixafor · Genzyme, a Sanofi Company · Oncology
Plerixafor is a CXCR4 antagonist that mobilizes hematopoietic stem cells from the bone marrow into peripheral blood for collection and transplantation.

Phase 3 pipeline (2)

Motixafortide+G-CSF · Guangzhou Gloria Biosciences Co., Ltd. · Oncology
Motixafortide is a CXCR4 antagonist that mobilizes hematopoietic stem cells from bone marrow into peripheral blood, used in combination with G-CSF (granulocyte-colony stimulating factor) to enhance stem cell mobilization for transplantation.
Generic = Plerixafor · Genzyme, a Sanofi Company · Oncology
Plerixafor is a CXCR4 chemokine receptor antagonist that mobilizes hematopoietic stem cells from the bone marrow into peripheral blood.